A carregar...

Safety of the 9-Valent Human Papillomavirus Vaccine

BACKGROUND: The 9-valent human papillomavirus vaccine (9vHPV) was approved for females and males aged 9 to 26 years in 2014. We analyzed postlicensure surveillance reports to the Vaccine Adverse Event Reporting System (VAERS). METHODS: We searched VAERS data for US reports of adverse events (AEs) af...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pediatrics
Main Authors: Shimabukuro, Tom T., Su, John R., Marquez, Paige L., Mba-Jonas, Adamma, Arana, Jorge E., Cano, Maria V.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6935554/
https://ncbi.nlm.nih.gov/pubmed/31740500
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1542/peds.2019-1791
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!